Molly C Carr MD
Diabetes, Lipid Metabolism, Obesity
VP - Clinical head of Insulins and Glucagon Development- Eli Lilly
Join to View Full Profile
3400 Civic Center Blvd2nd Floor, Suite 310 SPhiladelphia, PA 19106
Phone+1 215-662-2300
Fax+1 215-614-0418
Dr. Carr is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Molly Carr is an endocrinologist in Philadelphia, PA and is affiliated with Hospital of the University of Pennsylvania. She received her medical degree from Columbia University College of Physicians & Surgeons and has been in practice 23 years. She specializes in diabetes, lipid metabolism, and obesity and is experienced in non-alcoholic fatty liver disease, obesity and obesity-related disorders, endocrinology, hyperlipidemia, and adipose tissue.
Clinical Expertise
- Non-alcoholic fatty liver disease, Diabetes mellitus, Obesity and obesity-related disorders, Lipid metabolism disorders, Endocrinology, Hyperlipidemia, Medical weight loss, Adipose Tissue, Experimental Diabetes Mellitus, Nash, Prospective Studies
Education & Training
University of WashingtonFellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 2000- University of WashingtonResidency, Internal Medicine, 1994 - 1997
Columbia University Vagelos College of Physicians and SurgeonsClass of 1994
Certifications & Licensure
PA State Medical License 2008 - 2022
IL State Medical License 2004 - 2008
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 2 citationsInsulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.Carol Wysham, Harpreet S Bajaj, Stefano Del Prato, Denise Reis Franco, Arihiro Kiyosue
The New England Journal of Medicine. 2024-12-12 - 3 citationsOnce-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.Richard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, Yukiko Onishi, Vishali Vijayanagaram
Lancet. 2024-09-21 - 9 citationsOnce-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.Richard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, Molly C Carr, Juliana M Bue-Valleskey
Diabetes, Obesity & Metabolism. 2024-08-01
Authored Content
- Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programmeApril 2024
Press Mentions
These Are the Bedside Concerts Comforting Virus PatientsMay 4th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
